Archive for the ‘Research Projects’ Category
UPenn Alumni Gift $25M for Facility Focused on BRCA-Mutated Cancers
Last Updated on Wednesday, 9 May 2012 11:12 Written by Editor Wednesday, 9 May 2012 11:12
The University of Pennsylvania has been gifted $25 million by alumni Mindy and Jon Gray to establish the Basser Research Center (BRC), focused on the treatment and prevention of cancers associated with hereditary BRCA mutations. Located at Penn’s Abramson Cancer Center (ACC) at the Perelman School of Medicine, the Basser Center will contribute to all stages of research related to BRCA-related cancer detection, prevention, treatment, and care.
The gifted funds will establish a professorship, enhance core technologies including bioinformatics and DNA vaccine production, and establish the Basser Prize for cutting-edge research. The center is named after Mindy Gray’s sister, Faith Basser, who died of ovarian cancer aged 44. “We hope that the Basser Research Center will eliminate BRCA-related cancer and, in doing so, provide a road map for curing other genetic diseases,” Mindy and Jon Gray state.
“In creating this first-of-a-kind center, the Grays’ gift endows Penn researchers and clinicians with the crucial resources reuiqred to identify innovative ways to prevent and treat inherited diseases,” adds UPenn president Amy Gutmann.
The ACC currently supports 300 cancer research scientists, and has acted as an NIH-designated Comprehensive Cancer Center for over 30 years.
Source: http://www.genengnews.com/
Posted under North America, Oncology Research, Press Releases, Research Projects, RNA Reasearch | No Comments
Eleven Increases Series A Fundraising to $45M for Protein Therapeutics Pipeline
Last Updated on Tuesday, 8 May 2012 10:58 Written by Editor Tuesday, 8 May 2012 10:58
Eleven Biotherapeutics secured $20 million from new and existing investors in an extension to its Series A financing, which takes the total raised to $45 million. JAFCO joined the fundraising round as new investor together with financial input from existing investors Third Rock Ventures and Flagship Ventures.
Eleven Bio will use the funds to progress its initial protein therapeutic candidate EBI-005 into clinical development as a topical treatment for surface of the eye diseases as well as progress its earlier-stage pipeline. Initial clinical development of the interleukin-1 receptor antagonist is expected to start during 2012 for the treatment of dry eye syndrome. The firm cialms EBI-005 is the first rationally designed IL-1 receptor inhibitor for topical administration to be optimized for the treatment of drye eye disease and other ocular surface inflammatory disorders.
“This financing provides us with a strong financial foundation and firmly validates our investors’ enthusiasm for Eleven’s ability to develop novel, best-in-class protein therapeutics,” comments CEO Abbie Celniker, Ph.D.
Eleven is exploiting its AMP-Rx platform for the rational design of what it calls ‘fit for purpose’ therapeutic proteins that display the optimum physical, efficacy, and selectivity characteristics. Besides EBI-005, the firm’s preclinical pipeline includes an anti-IL-6 candidate against autoimmune and inflammatory disease, an IL-17 receptor antagonist for the potential treatment of ocular inflammation and uveitis, and an anti-myostatin antibody for treating muscle wasting. Early-stage research programs are in progress in the fields of hematology, immunosuppression, metabolism, inflammation, and gout therapy.
Source: http://www.genengnews.com/
Posted under BioInformatics, North America, R & D, Reports, Research Projects | No Comments
Kineta, Universities of Washington and Texas Win $8.1M for Antiviral Biodefense Drugs
Last Updated on Tuesday, 8 May 2012 10:54 Written by Editor Tuesday, 8 May 2012 10:54
A collaboration between Kineta, the University of Washington, and the University of Texas Medical Branch has been awarded $8.1 million in funding by the National Institute of Allergy and Infectious Diseases (NIAID) to develop antiviral drugs against potential biothreat agents as Ebola, plague, and Japanese encephalitis.
Researchers at the University of Washington’s NIH-sponsored Center for the Study of Immune Mechanisms of Virus Control have been working to understanding the basis of the body’s innate immunity to virus infection and the intracellular processes and virus-host interactions that control viral replication. The program will build on existing collaborations between Kineta and the University of Washington, including ongoing NIAID-funded research to develop antiviral drugs and vaccine adjuvants.
As part of the latest NIAID partnership, Kineta will lead drug optimization and in vivo pharmacology work, and scientists at the University of Washington will provide additional bioinformatics and systems biology genomics analysis. Collaborators at the University of Texas Medical Branch’s Galveston National Laboratory will oversee research on biosafety level 4 viral agents, including Ebola and Nipah viruses.
“This award enables us to push further and work with more high-priority viruses,” comments University of Washington professor Michael Gale Jr., Ph.D., principal grant investigator. “These diseases are major concerns of the U.S. government for their risk of sparking a pandemic and their potential use as bioterrorist weapons. By utilizing an innate immune pathway we hope to develop better drugs that won’t be outsmarted by viral mutation.”
Established in 2007, Kineta is developing drugs that act at the level of the innate and adaptive immune systems to treat infectious diseases and autoimmune disorders. Its primary target is retinoic acid inducible gene I protein (RIG-1), a key element of the innate immune system. Kineta says it has identified compounds that can influence RIG-1 and trigger natural anti-infection immune responses. The aim is to develop broad-based antiviral products against a range of infectious diseases such as HIV, hepatitis C, influenza, and West Nile Virus, and also exploit the RIG-1 platform to generate vaccine adjuvants.
Source: http://www.genengnews.com/
Posted under BioInformatics, North America, Press Releases, R & D, Research Projects | No Comments
Transcriptional Diversity Found in Circulating Tumor Cells from Individual Breast Cancer Patients
Last Updated on Tuesday, 8 May 2012 10:44 Written by Editor Tuesday, 8 May 2012 10:44
Scientists have shown that there is considerable transcriptional diversity between individual circulating tumor cells (CTCs) found in the blood of a single cancer patient, indicating that multiple treatments may be required to adequately kill off a patient’s cancer. Researchers led by a team at Stanford University used an immunomagnetic enrichment device technique known as MagSweeper to isolate CTCs from blood samples taken from breast cancer patients. The investigators then used microfluidic-based single-cell transcriptional profiling to look at the expression of 87 cancer-associated and reference genes in individual CTCs.
The results, reported in PLoS One, showed that there was significant heterogeneity in the transcription profiles of CTCs released into the blood, even among those from a single patient. Importantly, the expression profiles of all CTCs were very different from those of seven different primary and metastatic human breast cancer cell lines that are widely used for drug discovery and in vitro drug testing. “Our finding suggests that perhaps they’re not that helpful as models of spreading cancers,” claims lead investigator Stefanie S. Jeffrey, M.D., professor of surgery and chief of surgical oncology research at Stanford’s Department of Surgery.
The researchers describe their findings in a paper titled “Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.”
The treatment of metastatic cancer is determined largely by biomarkers from the primary tumor, despite the fact that metastatic tumors and primary tumors may be very different. Given that metastases are seeded at distal sites by CTCs released into the bloodstream, a method for accurately profiling such cells could provide valuable information for guiding therapy, the authors note. However, accurate characterization of CTCs is hampered both due to contamination with white blood cells and the limited sensitivity of analytical methods, which means analyses may have to carried out on pooled CTCs.
To demonstrate that single-cell transcription profiling is possible for CTCs, the team used the MagSweeper enrichment technology to isolate CTCs from breast cancer patient blood samples, and then applied microfluidic-based single-cell transcriptional profiling technique to determine the expression levels of 87 genes in individual CTCs. Blood samples were taken from 20 breast cancer patients with primary tumors, and 30 patients with metastatic disease. Of the 87 genes evaluated, 31 were consistently detected in at least 15% of the CTCs analyzed. Apart from three reference genes that were expressed in all the CTCs, the 28 remaining genes most commonly expressed were found to be relevant to nine basic functional categories: epithelial phenotype, epithelial mesenchymal transition, metastasis, PI3K/AKT/mTOR pathway, apoptosis, cell proliferation, DNA repair, cell metabolism, and stem cell phenotype.
Clustering analyses indicated that while the transcription profiles of CTCs varied considerably, they fell into two broad groups, both of which could be present in the same patient. Cluster I represented a relatively small proportion of the CTCs which, in comparison with cluster II, were characterized by stronger expression of S100A9, CD24, VIM, CXCR4, MAPK14, AKT2, PIK3R1, CTNNB1, CD44, and ZEB2. Importantly, both clusters robustly expressed a number of metastasis-associated genes.
Of particular note was the finding that the CTCs were almost exclusively triple negative (i.e., lacking Er, PR, and Her2 expression), irrespective of whether the patient’s primary tumor was triple negative or not. “Loss of expression of Er/PR/Her2 in CTCs noted in our particular patient sample could explain why therapies that target these biomarkers may fail to control end-stage disease,” professor Jeffrey et al point out.
And surprisingly, all the CTC transcription profiles differed greatly from those of three commonly used primary and four metastatic human breast cancer cell lines. “Overall, expression patterns of <10% (2/28) common tumor-associated gene profiles of CTCs were recapitulated by a subset of tumor cell line models,” the investigators write.
“Although CTC heterogeneity between patients is well recognized, an important finding in our study was that individual CTCs did not cluster by patient or disease stage (primary cancer vs. metastatic cancer), which again supports the concept that these cells belong to subpopulations with phenotypes fundamentally different from pooled tumor tissue,” they conclude. Studying and phenotyping the primary tumor alone may lead to suboptimal treatment selection … Our finding of CTC variability is consistent with primary and metastatic tumor heterogeneity and suggests that single cell phenotyping of CTCs is a practical approach to exploit this variability for the effective implementation of molecular guided cancer therapy on a more comprehensive scale than possible with mutational analysis of a few known genes.”
Source: http://www.genengnews.com/
Posted under North America, Press Releases, R & D, Research Projects, RNA Reasearch | No Comments
Islet Licenses Yale IP to Identify Beta Cell Death Before Diabetes Manifests
Last Updated on Tuesday, 8 May 2012 10:41 Written by Editor Tuesday, 8 May 2012 10:41
Islet Sciences negotiated an exclusive license to a diagnostic technology developed at Yale University that it says can identify beta cell death and help diagnose diabetes well before clinical symptoms present. The IP is based on the detection of circulating hypomethylated B cell-derived DNA, as a biomarker of B cell destruction.
Islet Sciences is focused on the development of transplantation therapies for diabetes based on its porcine islet cell and polymer microencapsulation technologies. The firm’s initial product, Islet Sciences-P™, is being developed as a ready-to-use vialed suspension of microencapsulated porcine islet cells for injection into the abdominal cavity.
In April Islet acquired DiaKine Therapeutics, which is developing a pipeline of treatments for diabetes. DiaKine’s most advanced product, Lisofylline, is in Phase II development as an intravenously administered adjunct therapy to islet cell transplantation. The drug is designed to improve the function of insulin-producing islet cells and protect them from damage and premature death associated with type 1 diabetes. A subcutaneous formulation of Lisofylline is in addition being evaluated in a Phase I study in newly diagnosed type 1 diabetes patients.
DiaKine’s preclinical pipeline includes a range of orally bioavailable immune modulators, including candidates for the treatment of latent autoimmune diabetes in adults and insulin-dependent type 2 diabetes, and diabetic nephropathy and retinopathy. Last month DiaKine received two separate grants from the NIH ($1.83 million) and Iacocca Foundation ($250,000).
Source: http://www.genengnews.com/
Posted under North America, Press Releases, R & D, Research Projects, RNA Reasearch | No Comments
Celgene Pays Epizyme $90M for Ex-U.S. Rights to Histone Methyltransferase Inhibitor
Last Updated on Monday, 7 May 2012 04:53 Written by Editor Monday, 7 May 2012 04:53
Celgene is paying Epizyme $90 million up front to established a partnership focused on the discovery, development, and commercialization of histone methyltransferase (HMT)-inhibiting drugs for genetically defined cancers. The up-front fee includes an equity investment in Epizyme and gives Celgene exclusive immediate ex-U.S. rights to its partner’s existing DOT1L HMT inhibitor program against mixed lineage leukemia (MLL).
Under terms of the deal Celgene also retains an exclusive option to license ex-U.S. rights to other Epizyme HMT inhibitor programs over an initial three-year period. Epizyme retains all U.S. rights to resulting products, and could earn up to another $160 million in milestones for each HMT inhibitor licensed by Celgene, and potentially double-digit royalties on ex-U.S. sales. The firms will work jointly to discover and develop HMT inhibitors, and will co-fund global development of collaborative programs.
Celgene’s expertise in epigenetic cancer therapies and Epizyme’s histone myethyltransferase platform are highly complementary, the partners claim. “Through this collaboration, Epizyme gains access to Celgene’s leading drug development resources, enabling us to substantially increase the breadth and depth of our efforts while retaining U.S. rights to our pipeline of personalized therapies,” comments Robert Gould, Ph.D., Epizyme CEO.
Epizyme is focused on the discovery and development of small molecule HMT inhibitors. The firm’s initial therapeutic target is MLL, a form of acute leukemia characterized by the presence of a chromosomal alteration (MLL-translocation) that recruits DOT1L activity to aberrant gene locations, leading to increased expression of specific gene products that drive leukemia cell proliferation. The small molecule DOT1L inhibitor is designed to selectively kill MLL cells, while sparing cells that don’t carry the MLL-translocation.
DOT1L is being developed in collaboration with the Leukemia and Lymphoma Society. Last month Eipzyme reported achieving a preclinical milestone in the program, and said it has to date received $2.6 million of potentially $7.5 million in funding under the partnership to support the DOT1L program through Phase I development.
The firm’s second lead program, EZH2, is in development in partnership with Eisai for the treatment of certain nonHodgkin lymphomas and breast cancer subtypes. The compound is designed to target the catalytic center of a multiprotein complex known as polycomb repressive complex 2 (PRC2). Epizyme and Eisai inked their deal for the EZH2 program back in March 2011.
Source: http://www.genengnews.com/gen-news-highlights/celgene-pays-epizyme-90m-for-ex-u-s-rights-to-histone-methyltransferase-inhibitor/81246684/
Posted under DNA Reasearch, North America, Press Releases, R & D, Research Projects | Comments Off
http://www.genengnews.com/gen-news-highlights/researchers-find-gene-key-to-maintaining-lung-cancer-stem-cells-promoting-tumor-initiation-and/81246678/
Last Updated on Monday, 7 May 2012 04:47 Written by Editor Monday, 7 May 2012 04:47
Scientists have identified a single gene that appears to be central to the maintenance of non-small cell lung cancer (NSCLC) cancer stem cells, as well as the initiation of tumor formation, growth and metastasis in vivo. A Mayo Clinic College of Medicine team found that cancer stem cells (CSCs) in oncosphere cultures demonstrated high expression levels of matrix metalloproteinase-10 (Mmp-10; or stromelysin 2), and that knocking down Mmp10 expression in these cells resulted in the loss of stem cell markers and the inhibition of oncosphere growth, clonal expansion, and tumor development. Mmp10-deficient oncospheres were in addition far less able to initiate tumor development than unmodified oncospheres when injected into experimental mice.
Reporting their findings in PLoS One, Alan P. Fields, M.D., and colleagues say subsequent analysis of gene expression data from human cancers highlighted a strong correlation between tumor Mmp10 expression and metastasis in a range of tumor types. “Our data demonstrate for the first time that Mmp10 is a critical lung cancer stem cell gene and novel therapeutic target for lung cancer stem cells,” they conclude. The investigators’ results are published in a paper titled “Matrix Metalloproteinase-10 Is Required for Lung Cancer Stem Cell Maintenance, Tumor Initiation and Metastatic Potential.”
MMPs have previously been implicated in lung tumor proliferation, invasion, and metastasis. The Mayo team’s own prior work suggested that Mmp10 is needed for transformed growth and invasion of human NSCLC cells in vitro, and mediates tumor initiation through the control of tumor-initiating bronchio-alveolar stem cell expansion.
Building on these findings the investigators have now looked more closely at the role of Mmp10 in the maintenance and tumorigenic potential of fully transformed mouse lung CSCs, a cell population characterized by stem-like properties including increased anchorage-independent growth in vitro, and enhanced tumor initiation, growth, and metastatic spread as orthotopic tumors in syngeneic mice.
The CSCs in these oncosphere cultures were found to express high levels of mRNAs for numerous genes associated with stem cell phenotype, and also high levels of Mmp10, but not other MMPs previously linked with lung cancer. The cultures in addition secreted much higher levels of Mmp10 protein into the medium in comparison with parental or redifferentiated cultures. As expected, oncosphere cultures demonstrated a loss of stem cell markers and Mmp10 expression when allowed to redifferentiate in adherent culture.
Notably, using an Mmp10-targeting RNAi to knock down Mmp10 mRNA expression in the oncosphere cultures led to an inhibition of transformed growth, loss of stem cell markers, and inhibition of clonal expansion, without impacting on cell viability. These effects could be restored by the addition of exogenous Mmp10.
Initial tests in vivo showed that while transplanting cells from oncosphere cultures into the lungs of syngeneic mice routinely led to the development of large tumors, cells from Mmp10-knockdown cultures generated fewer and small tumors, and also fewer metastases.
Importantly, the role of Mmp10 in tumorigenesis related to the gene’s expression by CSCs specifically, and not by other cells in the tumor environment. When the researchers injected unmodified oncospheres into Mmp10 knockout mice, tumor growth, size, and metastasis were equivalent to those resulting from the injection of unmodified oncospheres into wild-type syngeneic mice. This indicates that “Mmp10 expressed by oncospheres, but not from Mmp10 produced by other tumor-associated cells, is critical for tumor formation,” they write.
In a final set of analyses, the team analyzed publicly available gene-expression datasets of human tumors and found a strong positive correlation between Mmp10 expression and metastatic potential not only in human NSCLC, but also in colorectal cancer, melanoma, breast cancer, renal cell carcinoma, and prostate cancer.
The observation that Mmp10 appears to play a dual role in cancer, both in terms of maintaining the cancer stem cell population and facilitating metastasis, was an unexpected finding, the investigators note. Most other MMPs are expressed in the tumor microenvironment and cells and tissues surrounding the tumor, where they act to modify the tumor environment and facilitate cancer cell spread, Dr. Field explains. Conversely, “Mmp10 acts to keep these cancer stem cells healthy and self-renewing, which also helps explain why these cells escape conventional chemotherapy that might destroy the rest of the tumor.”
The team is now trying to define the mechanism by which Mmp10 stimulates the growth of cancer stem cells, and identify the design of inhibitors that block its activity. “Given the dual role in cancer stem cells and metastasis, targeting Mmp10 may be especially effective in treating these tumors,” he concludes.
Source: http://www.genengnews.com/gen-news-highlights/researchers-find-gene-key-to-maintaining-lung-cancer-stem-cells-promoting-tumor-initiation-and/81246678/
Posted under North America, Press Releases, R & D, Research Projects | Comments Off
Novo Nordisk, Kennedy Institute Partner on Rheumatoid Arthritis Drug and Biomarker R&D
Last Updated on Monday, 7 May 2012 04:33 Written by Editor Monday, 7 May 2012 04:33
Novo Nordisk is partnering with Oxford University’s Kennedy Institute of Rheumatology in the U.K. for the discovery and development of new biomarkers and drug targets for rheumatoid arthritis and other inflammatory autoimmune diseases. Under terms of the agreement, Novo Nordisk will fund 10 researchers at the Kennedy Institute to work within the partnership.
The Institute has in the past made key discoveries in the field of rheumatoid arthritis pathobiology, and its head, professor Sir Marc Feldman, M.D., was one of the co-discoverers of anti-TNF as a therapeutic approach to the disease. The translational research center will work in partnership with Novo Nordisk to apply its expertise to the discovery of new treatments.
“As a translational research center, we are keen to do clinical research on truly innovative ideas that have the potential to improve how patients with autoimmune inflammatory disease are treated today,” professor Feldman remarks. “We will work closely together with Novo Nordisk to apply the most advanced translational research approaches available for discovering new mechanisms and validating drug targets and candidates in autoimmune inflammatory disease in a variety of human disease tissue types and at different stages of disease, to ensure comprehensive characterization of each compound’s clinical potential.”
Source: http://www.genengnews.com/gen-news-highlights/novo-nordisk-kennedy-institute-partner-on-rheumatoid-arthritis-drug-and-biomarker-r-d/81246669/
Posted under Drug Development, North America, Press Releases, R & D, Research Projects | Comments Off
Scientists Identify Potential Target for Treating Cocaine Addiction
Last Updated on Monday, 7 May 2012 04:24 Written by Editor Monday, 7 May 2012 04:24
Scientists report new insights into the mechanism by which repeated exposure to cocaine induces addiction. The studies in mice demonstrate that cocaine downregulates the active form of Rac1, a small GTPase known to control actin remodelling, and that this leads to enhanced actin turnover, and increases the density of immature dendritic spines on nucleus accumbens (NAc) neurons in the brain’s key reward center.
The researchers, led by a team at Mount Sinai School of Medicine’s Fishberg Department of Neuroscience and Friedman Brain Institute, showed in mice that overexpression of a dominant negative mutant of Rac1 or local knockout of the native gene was enough to increase the density of immature dendritic spines on the NAc neurons, without cocaine administration. Encouragingly, transiently increasing levels of Rac1 blocked the addiction-causing effects of repeated cocaine use and the accompanying neural changes.
Reporting their findings in Nature Neuroscience, Eric J. Nestler and colleagues suggest their results could help in the design of new treatments for cocaine addiction. Their paper is titled “Rac1 is essential in cocaine-induced structural plasticity of nucleus accumbens neurons.”
“The research gives us new information on how cocaine affects the brain’s reward center and how it could potentially be repaired,” Dr. Nestler says. “This is the first case in the brain in vivo where it’s been possible to control the activity of a protein, inside nerve cells in real time. Our findings reveal new pathways and targets.”
Source: http://www.genengnews.com/gen-news-highlights/scientists-identify-potential-target-for-treating-cocaine-addiction/81246662/
Posted under North America, Press Releases, R & D, Research Projects | Comments Off
Device sought for early screening
Last Updated on Tuesday, 17 April 2012 05:13 Written by Editor Tuesday, 17 April 2012 05:13
By Carly Harrington
Posted April 15, 2012 at 4 a.m.
Every year when it’s time for her routine physical exam, Nancy Munro’s family practice physician will place electrodes to her chest and run an electrocardiogram to check the health of her heart.
The simple, low-cost EKG test, which records the electrical activity of a person’s heart, takes a matter of seconds and gives her doctor something to look at to determine if there are any problems.
Munro, a retired ORNL researcher, believes a similar method could be used to help primary care doctors detect signs of early Alzheimer’s disease and mild cognitive impairment.
“They only acquire data for 30 seconds, and the doctor can look at it and very quickly decide whether it looks OK or not. That’s the kind of thing we’re aiming for,” she said. “Our goal is to develop a device that can be used in the primary care setting, whether it’s a doctor’s office or a community hospital, that will quickly give a reliable discrimination between normal aging and possibly clinically significant memory problems.”
Munro has been collaborating with fellow scientists at ORNL and the universities of Kentucky and Tennessee to develop an early screening tool using data from an electroencephalogram, or EEG, which measures electrical activity in the brain.
The method was inspired by the work of fellow ORNL researcher Lee Hively, who had developed a way to analyze data, including EEG data, forewarning of epileptic seizures.
“As I got to know more about his research, we discussed the possibility of looking at other brain disorders, and one of the things we discussed was Alzheimer’s,” said Munro, whose mother-in-law had been severely affected by the disease.
The group conducted a pilot project using data collected by the University of Kentucky from three groups of patients — patients with no dementia symptoms, patients diagnosed with mild cognitive impairment and patients diagnosed with early Alzheimer’s.
An analysis done via a collaboration between ORNL and the University of Tennessee showed positive results in distinguishing between the three.
Meanwhile, a working memory test, which could be used in a memory disorders clinic, was added to the study.
When looking at the EEG signals from the different parts of the brain, the mild cognitive impairment group processed the data more like the Alzheimer’s folks did, Munro said.
“They’re showing more activity in a different part of the brain than what the normal pattern is.
“It’s parallel to the Alzheimer’s group, so it shows that there is a difference in how the brain is functioning between the normal and the mild cognitive impairment group,” she added.
The group is now in the process of seeking additional funding to expand its initial study.
Munro said their approach would give a better basis for knowing whether someone should be referred to a specialist or not.
It also could be used in the drug discovery process by providing a low cost way of assessing whether the compounds they’re trying to develop are helpful.
“What we’re trying to do is not aimed at untangling the disease mechanism at all,” she said.
“It’s trying to get at very early changes, just as early as possible so we can identify people and get treatment.”
Get Copyright Permissions © 2012, Knoxville News Sentinel Co.
Want to use this article? Click here for options!
© 2012 Knoxville News Sentinel. All rights reserved.
Source: http://www.knoxnews.com/staff/carly-harrington/
Posted under HT Screening, Nanotechnology, North America, Press Releases, R & D, Research Projects | Comments Off
Newborn Screening for Spinal Muscular Atrophy by Calibrated Short-Amplicon Melt Profiling
Last Updated on Tuesday, 17 April 2012 05:04 Written by Editor Tuesday, 17 April 2012 05:04
Steven F. Dobrowolski1,*,
Ha T. Pham2,
Frances Pouch-Downes3,
Thomas W. Prior4,
Edwin W. Naylor5 and
Kathy J. Swoboda6,7
+ Author Affiliations
1Department of Pathology, Children’s Hospital of Pittsburgh, Pittsburgh, PA;
2ARUP Laboratories, Salt Lake City, UT;
3Michigan Department of Community Health, Lansing, MI;
4Department of Pathology, Ohio State University, Columbus, OH;
5BioChem Genetics LLC, Isle of Palms, SC;
6Departments of Neurology and
7Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.
Abstract
BACKGROUND: The management options for the autosomal recessive neurodegenerative disorder spinal muscular atrophy (SMA) are evolving; however, their efficacy may require presymptom diagnosis and continuous treatment. To identify presymptomatic SMA patients, we created a DNA-based newborn-screening assay to identify the homozygous deletions of the SMN1 (survival of motor neuron 1, telomeric) gene observed in 95%–98% of affected patients.
METHODS: We developed primers that amplify a 52-bp PCR product from homologous regions in the SMN1 and SMN2 (survival of motor neuron 2, centromeric) genes that flank a divergent site at site c.840. Post-PCR high-resolution melt profiling assessed the amplification product, and we used a unique means of melt calibration to normalize profiles. Samples that we had previously characterized for the numbers of SMN1 and SMN2 copies established genotypes associated with particular profiles. The system was evaluated with approximately 1000 purified DNA samples, 100 self-created dried blood spots, and >1200 dried blood spots from newborn-screening tests.
RESULTS: Homozygous deletion of SMN1 exon 7 produced a distinctive melt profile that identified SMA patients. Samples with different numbers of SMN1 and SMN2 copies were resolved by their profiles. All samples with homozygous deletions were unambiguously recognized, and no normal sample was misidentified as a positive.
CONCLUSIONS: This assay has characteristics suitable for population-based screening. A reliable screening test will facilitate the identification of an SMA-affected cohort to receive early intervention to maximize the benefit from treatment. A prospective screening trial will allow the efficacy of treatment options to be assessed, which may justify the inclusion of SMA as a target for population screening.
Received for publication January 21, 2012.
Accepted for publication March 15, 2012.
© 2012 The American Association for Clinical Chemistry
Source: http://www.clinchem.org/content/early/2012/04/09/clinchem.2012.183038.short?rss=1
Posted under HT Screening, North America, Press Releases, Research Projects | Comments Off
Europe plans molecular screening center for translational research
Last Updated on Tuesday, 17 April 2012 04:28 Written by Editor Tuesday, 17 April 2012 04:28
Lucas Laursen
05 April 2012
Almost a decade ago, the US National Institutes of Health kicked off its Molecular Libraries Initiative to provide academic researchers with access to the high-throughput screening tools needed to identify new therapeutic compounds. Europe now seems keen on catching up.
Last month, the Innovative Medicines Initiative (IMI), a €2 billion ($2.6 billion) Brussels-based partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), invited proposals to build a molecular screening facility for drug discovery in Europe that will combine the inquisitiveness of academic scientists with industry know-how. The IMI’s call for tenders says the facility will counter “fragmentation” between these sectors.
The IMI will offer €80 million over five years to the consortium selected to build up and manage a centralized screening infrastructure and a library of up to 500,000 compounds. Expressions of interest from qualified academic-industry partnerships are due in mid-May.
Major pharmaceutical companies have more experience with high-throughput screening than do most academic institutes. Yet companies often limit tests of their closely held candidate chemicals to a fraction of potential disease targets. By pooling chemical libraries and screening against a more diverse set of targets—and identifying more molecular interactions—both academics and pharmaceutical companies stand to gain, says Hugh Laverty, an IMI project manager.
The IMI already has commitments from seven members of the EFPIA to contribute 50,000 compounds each, and future academic partners are expected to donate between 100,000 and 200,000 total. (The NIH similarly has around 300,000 chemically diverse compounds in its small-molecule repository.)
Onlookers note the challenge of handling so many molecular candidates. Whoever manages the IMI’s ‘European Screening Centre’ will need to develop an efficient process for preselecting compounds to make the high-throughput screening worth the cost to taxpayers, says Robert Damoiseaux, scientific director of the Molecular Screening Shared Resource (MSSR) at the University of California–Los Angeles. Damoiseaux recommends that Europeans look across the pond for insight on this: “It’s certainly really useful to compare notes with American researchers and have a look at which lessons can be learned, what paradigms worked and what didn’t.”
Ultimately, a facility as large as the proposed European Screening Center should be more efficient than the smaller sites that already exist around Europe, says Gerardo Turcatti, who directs the Biomolecular Screening Facility at the Swiss Federal Institute of Technology in Lausanne. He adds, however, that sorting out intellectual property in any collaboration that also involves industrial applications will be a challenge.
Laverty says the IMI will help the winning consortium negotiate the particulars with the industry partners. “We’re very aware of intellectual property concerns,” he explains, adding that identifying a promising compound might trigger milestone payments to a compound’s contributor.
Source: http://www.nature.com/nm/journal/v18/n4/full/nm0412-477a.html
Posted under Compound Screening, Europe, Press Releases, R & D, Research Projects | Comments Off
RiboMed Launches Improved Prognostic Multi Biomarker Epigenetic Test for Brain Cancer
Last Updated on Thursday, 12 April 2012 06:58 Written by Editor Thursday, 12 April 2012 06:58
RiboMed Clinical Services Laboratory (RCSL), a CLIA-certified subsidiary of RiboMed Biotechnologies, today announced the release of a multi-marker methylation prognostic test for grading gliomas, the most common type of brain cancer. The test robustly analyzes 8 genes for differential methylation on FFPE (Formalin Fixed Paraffin Embedded) tumor samples to determine the G-CIMP (Glioma CpG Island Methylation Phenotype) score. The G-CIMP score correlates with patient survival and provides a new tool for physicians as they plan the patient’s treatment. This unique multiple DNA Methylation biomarker test, developed and validated by RCSL and commercialized and marketed by Castle Biosciences, Inc (Friendswood, TX), offers significant improvements in sensitivity, patient sample requirements and reproducibility over the bisulfite DNA methylation platform. These improvements were achieved by utilizing RiboMed’s proprietary and patented bisulfite-free Abscription®-based MethylMeter® platform.
As noted by RiboMed CEO Dr. Michelle Hanna, “The unparalleled sensitivity, accuracy, and reproducibility offered by the Abscription®-based G-CIMP test, coupled with its ability to efficiently assess multiple methylation biomarkers in FFPE patient samples, makes this the best in class option for prognostic glioma testing. Furthermore, MethylMeter is directly applicable to the development of a broad range of new diagnostic, theranostic, and companion diagnostic DNA methylation based assays, particularly those utilizing FFPE samples.” RCSL’s clinical diagnostic assay pipeline includes tests for ovarian and lung cancers.
The G-CIMP biomarker panel was originally discovered and correlated to glioma patient survival by researchers at the MD Anderson Cancer Center (MDACC) and exclusively licensed to Castle Biosciences. After initial unsuccessful attempts at commercialization using traditional bisulfite-based methylation detection platforms, Castle Biosciences adopted RiboMed’s platform based on its ability to assay biomarker DNA Methylation profiles efficiently in degraded DNA found in FFPE patient tumor samples. RiboMed subsequently developed a robust G-CIMP biomarker test that shows concordance with the MDACC clinical DNA Methylation data correlating CIMP Methylation status with patient survival times. RCSL is now performing this test as a service for Castle. Multiple studies have provided ample evidence of clinically significant inter-observer variation of the histological typing and grading of glioma. This variation is clinically significant as treatment plans are based upon grade. The purpose of the G-CIMP biomarker test is to provide objective information to improve grade-related prognosis. “When traditional bisulfite-based technologies were found to be unsuitable for this FFPE assay, RiboMed’s bisulfite-free methylation detection platform effectively circumvented the problems associated with these traditional technologies enabling the rapid development of an accurate and reproducible FFPE glioma tumor assay” stated Castle Biosciences CEO Derek Maetzold. “We are very excited to partner with RiboMed in offering the DecisonDX G-CIMP test since it will significantly improve glioma tumor grading and become the standard of care for these patients.”
About RiboMed: RiboMed Biotechnologies (www.ribomed.com) is a molecular diagnostic company with a focus on Epigenetic Diagnostics and Theranostics in Oncology. The Company develops and provides products, services, and tests for disease screening, diagnostics, theranostics, post-treatment monitoring, and drug development utilizing its proprietary and patented technology platforms for biomarker detection (Abscription®) and methylated DNA isolation and quantification (MethylMagnet® and MethylMeter®). RiboMed Clinical Services Laboratory (RCSL), a fully compliant CLIA certified laboratory subsidiary, offers sensitive and quantitative DNA Methylation profiling clinical assay development services which provide reliable results even with Formalin Fixed Paraffin Embedded tissues.
About Castle: Castle Biosciences is a cancer based molecular diagnostics company whose mission it is to serve individuals afflicted with rare or orphan cancers and those who care for them. The company has commercially available tests for use in eye cancer (uveal melanoma) and brain cancer (glioblastoma). The company’s tests can only be ordered by a licensed physician.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of RiboMed and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company’s control, and may turn out to be materially different. RiboMed expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.
Source: https://ireach.prnewswire.com/
Posted under DNA Reasearch, Nanotechnology, North America, Press Releases, Research Projects, RNA Reasearch | Comments Off
Roche has extended its serology panel to include a new generation Elecsys anti-HCV II
Last Updated on Tuesday, 10 April 2012 07:24 Written by Editor Tuesday, 10 April 2012 07:24
With an estimated 216,000 individuals chronically infected in the UK (England 161,000, Northern Ireland 4,000, Scotland 39,000, Wales 12,000), hepatitis C (HCV) remains a major public health problem; and HCV-related end stage liver disease and mortality continue to increase1.
The Health Protection Agency states that it is necessary to sustain and enhance efforts to raise awareness, prevent new infections, increase diagnosis, and treat more individuals with infection.
The new Roche Elecsys anti-HCV II assay can play an effective part in this strategy, as it is used to demonstrate the presence of antibodies against HCV during acute and chronic stages of disease, and after a passed infection.
Due to the high rate of asymptomatic infections, clinical diagnosis of hepatitis C is difficult and screening assays are of major importance.
The Roche Elecsys anti-HCV II assay provides 100% clinical sensitivity for all known genotypes, leading to early detection of infection and patient-oriented decision making.
With high specificity in blood donors (99.84%) and samples from clinical routine, pregnant women and dialysis patients, use of the Elecsys anti-HCV II assay increases laboratory testing efficiencies.
To optimise workflows and provide operational cost savings, the ready-to-use liquid reagents have a long onboard stability of 31 days on all Roche immunoassay platforms.
The new assay complements the Roche serology assay menu that includes assays for Hepatitis A, Hepatitis B, Hepatitis C, HIV, TORCH, Herpes, Syphilis and other infectious diseases.
Source: http://www.laboratorytalk.com/news/roe/roe202.html
Posted under Europe, Hepatitis Research, R & D, Reports, Research Projects | Comments Off
Scripps Florida scientists to create new screening tests for HCV treatment discovery
Last Updated on Monday, 9 April 2012 07:41 Written by Editor Monday, 9 April 2012 07:41
Scientists from the Florida campus of The Scripps Research Institute have been awarded just over $1 million from the National Institutes of Health for a three-year study to develop new high-throughput screening tests to find compounds that disable a protein essential to hepatitis C virus (HCV) replication.
Timothy Tellinghuisen, a Scripps Florida associate professor, is the principal investigator for the study.
Hepatitis C is a slow-progressing disease that causes inflammation of the liver and affects some 170 million people worldwide, according to the Hepatitis Foundation International. Like the current approach to HIV/AIDS, a cocktail-based therapeutic approach, which uses multiple inhibitors targeting distinct aspects of the HCV life cycle, has emerged as one of the most promising.
In the search for new treatments against HCV, it has become critical to develop novel targets to attack. Tellinghuisen’s new research is focused on a potentially potent, but somewhat neglected, enzyme. This protease—an enzyme that breaks down proteins—is known as NS2, which is necessary for productive infections that produce new viruses and spread the infection among cells.
“The NS2 protein is needed for hepatitis C infections, but is poorly understood,” Tellinghuisen said. “The new grant will help us develop potential chemical tools to look at the role of NS2 in HCV biology because we really don’t know how the protein works.”
Some recent studies suggest that the NS2 protease may be involved in altering gene expression in the host cell and in helping the virus defend against apoptosis or programmed cell death, in addition to the more direct roles for the protein in viral replication and particle assembly.
Tellinghuisen and his colleagues have already developed a small-scale screen to identify compounds that disrupt viral replication through NS2 protease activity.
“Our overall goal is to turn our small-scale NS2 assay into an assay appropriate for high-throughput small-molecule screening,” he said, noting that would give the team access to the more expansive Molecular Libraries Probe Production Centers Network (MLPCN) screening center program at Scripps Florida.
Source: http://www.scripps.edu/news/press/20120404tellinghuisen.html
Posted under Hepatitis Research, North America, Press Releases, Research Projects | Comments Off
Life’s building blocks grow close to home
Last Updated on Thursday, 5 April 2012 07:44 Written by Editor Thursday, 5 April 2012 07:44
hough life is a complicated brew, some of its ingredients can be plucked from Earth’s backyard instead of being imported from more distant interstellar fields.
In a new study, scientists suggest that complex organic molecules — such as the amino acids that build proteins and the ringed bases that form nucleic acids — grow on the icy dust grains that lived in the infant solar system. All it takes are high-energy ultraviolet photons to provoke the rearrangement of chemical elements in the grains’ frozen sheaths.
If making these organic ingredients happens this readily, then exoplanetary systems are probably seeded with the same fertile, organic pastures. “Anywhere you have ice and high-energy, ultraviolet radiation, this process is going to take place. And those are both pretty common in the universe,” says Dante Lauretta, a planetary scientist at the University of Arizona.
In the new work, reported online March 29 in Science, researchers began by simulating the early solar nebula, a swirling disk of gas and dust that surrounded the young sun until planets began forming about 4.5 billion years ago. Over a 1-million-year period, the team tracked the movement of 5,000 individual dust grains, tiny organic-toting particles covered in ices made from compounds like water, carbon dioxide, methanol, or ammonia.
“We wanted to know exactly what conditions those ice particles were seeing,” says coauthor Fred Ciesla, a planetary scientist at the University of Chicago. “It’s a turbulent environment, and every particle follows its own path.”
Most grains survived the million-year period, though some fell inward and were snatched by the sun.
Grains lofted above the disk’s plane met warmer temperatures and high-energy ultraviolet photons — the catalysts needed to convert elements in the simple ices to more complex molecules. In these types of reactions, photons striking chemical bonds create what study coauthor Scott Sandford calls “unhappy radicals and ions” — species that are highly reactive and ready to recombine. As warming temperatures cause the ices to evaporate, those elements can find partners and form new molecules.
Even though it’s relatively easy to create these rearranged molecules, scientists can’t really predict which will form because the chemical reactions don’t follow familiar rules. “It’s a bit like saying, ‘I’m going to give you 10 kinds of Lego blocks, feel free to stack them in any combination you want,’” says Sandford, an astrophysicist at NASA’s Ames Research Center in Mountain View, Calif.
But with enough photons slamming into enough dust grains in the early solar nebula, it’s hard to avoid making complex molecules this way, Ciesla says.
Astrobiologists have identified such molecules as being important in the story of life’s origins, and there’s abundant evidence that they can survive in space. Scientists autopsying meteorites that crashed to Earth have found amino acids and nucleobases in the space rocks.
In the lab, researchers have simulated how such compounds could be made astrochemically. By applying organic ices to tiny surfaces in a frigid vacuum, and then irradiating them, teams have produced an array of molecules, including one that spontaneously organizes itself into membranes, says Jason Dworkin, an astrobiologist at NASA’s Goddard Space Flight Center in Greenbelt, Md.
Swirling around the young sun, those organic-laden ice grains eventually clustered and clumped. The clumps grew into comets and asteroids that bore these molecules to Earth, depositing them in fiery collisions or lighting the infant skies with an organic-rich hailstorm. “I think it’s well established that extraterrestrial compounds were delivered in this way,” Dworkin says. It’s not yet clear how much the space travelers contributed to the population of organic compounds on Earth, but they are certainly a convenient mode of delivery. “If you want to build Lego castles, having Lego bricks falling out of the sky is not a bad idea,” Sandford says.
Flinging rocks at Earth is not the only way to deposit organics. “I’ve never felt I had to look for an extraterrestrial source of amino acids to understand how amino acids could have arisen on this planet,” says geochemist George Cody of the Carnegie Institution for Science in Washington, D.C. But lots of irradiated icy particles in the solar nebula, as Ciesla and Sandford have proposed, is a tantalizing natural reservoir, he says.
Scientists are still considering whether materials made on Earth helped litter the planet with organics. It seems likely, although any complex molecules would need to survive the young planet’s violent, fiery growth spasms, a period marked by magma oceans and extreme temperatures that would have destroyed any preexisting complex structure. Both extraterrestrial and homegrown processes probably played a role, Ciesla says. “These organics will be there to incorporate into planets as they form, or in later delivery, after the planets form, which could be interesting in terms of astrobiology.”
Soon, scientists should have a better idea of the array of molecules that live on asteroids. In 2016, NASA will fire a spacecraft at an asteroid, scrape off some of its surface, and return the samples to Earth. The OSIRIS-REx mission will aim for asteroid 1999 RQ36 (the subject of a renaming contest this fall) and return to Earth in 2023, carrying samples that researchers will examine for clues to the solar system’s early years.
“Any organic molecule is going to be interesting for deciphering the history of the solar system,” says Lauretta, the principal investigator for the mission. “But for tracing the origin of life, we really focus in on the building blocks.”
Life’s Legos growing nearby carries strong implications for the likelihood of such organic pastures in other planetary systems. “As far as the chemistry goes,” Dworkin says, “this appears universal.”
Back Story – Special delivery
Meteorites have yielded many types of complex organic molecules over the years. In 1970 scientists found protein-building amino acids in the Murchison meteorite, which landed in Australia the year before. More recently, last August, researchers found nucleobases (shown left), ringed structures that make up nucleic acids, inside space rocks that had landed in Antarctica. Some of the rocks contained molecules that are rare in Earthly biology, which strongly suggested an extraterrestrial origin. But what’s been unclear is how — and where — these molecules were cooked up. Earlier theories have pointed to synthesis in the larger cloud of gas from which the solar system formed, implying that life’s ingredients had been imported from farther away. Now it appears that these molecules can be readily made in Earth’s backyard — and in similar planetary neighborhoods all over the universe.
Source: http://www.sciencenews.org/view/generic/id/339541/title/Life%E2%80%99s_building_blocks_grow_close_to_home
Posted under BioInformatics, Bird Flu Research, North America, Reports, Research Projects | Comments Off
HTLV blood screening test from RTP diagnostics firm Avioq gets FDA OK
Last Updated on Thursday, 5 April 2012 07:36 Written by Editor Thursday, 5 April 2012 07:36
The U.S. Food and Drug Administration has approved a new test for blood donations, just the second test available to screen for two viruses linked to leukemia and neurologic disorders.
The blood test, developed by medical device company Avioq, detects antibodies to human T-lymphotropic virus type 1 (HTLV 1) and human T-lymphotropic virus type 2 (HTLV 2). In addition to screening blood donors for the presence of the viruses, the tests can help clinicians diagnose the viruses and other related diseases in patients. Avioq said the tests can also be used to screen organ donors.
Avioq, based in Research Triangle Park, North Carolina, is targeting a U.S. blood donation market that is estimated at 17 million donations a year. Both HTLV viruses can be transmitted by blood transfusion, reuse of syringes and breast feeding. Until now, the only FDA-approved test to screen for HTLV 1 and HTLV 2 is a product made by Abbott (NYSE:ABT). Dr. Karen Midthun, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement that the Avioq approval will allow for “greater flexibility to blood establishments and helping to assure the safety of the blood supply.”
Advertisement
HTLV 1 is a retrovirus that has been associated with adult T-cell leukemia and neurologic disorders tropical spastic paraparesis and HTLV 1-associated myelopathy. People who have these disorders have antibodies to HTLV 1. According to the FDA, HTLV 1 is regularly found in some Caribbean countries, southern Japan and possibly in some areas of Africa. In the United States, the virus has been found in leukemia patients, intravenous drug abusers as well as healthy individuals.
Avioq developed its HTLV tests under a 2010 partnership with Johnson & Johnson (NYSE:JNJ) subsidiary Ortho Clinical Diagnostics. Now that the test has been approved, Ortho Clinical will distribute the Avioq assay into the donor screening market. Avioq will handle sales to the clinical diagnostic market.
Source: http://www.medcitynews.com/2012/03/htlv-blood-screening-test-from-rtp-diagnostics-firm-avioq-gets-fda-o-k/
Posted under DNA Reasearch, North America, Reports, Research Projects | Comments Off
Charm Sciences Announces ROSA® FAST5 Family of 5 Minute Quantitative Mycotoxin Test Kits
Last Updated on Thursday, 5 April 2012 07:32 Written by Editor Thursday, 5 April 2012 07:32
Charm Sciences, Inc. is pleased to announce that the Charm® ROSA FAST5 family of quantitative mycotoxin tests will be launched at the Pet Food Forum held April 2-4, 2012 in Schaumburg, Illinois.
These 5 minute mycotoxin tests deliver quantitative detection that is rapid and accurate in feed and grain for aflatoxin, DON and fumonisin. Mycotoxins are toxic when ingested by humans and animals and require fast, accurate tests that are necessary for safe product to go to market. The Rapid One Step Assay (ROSA) technology makes testing simple in a convenient lateral flow strip format. Diluted extract is applied to each test strip, incubated for 5 minutes, and read on the ROSA-M Reader.
Charm® ROSA FAST5 family of quantitative mycotoxin tests includes:
ROSA FAST5 DON Quantitative Test Kit – GIPSA approved commodities for: Barley, Corn, DDGS, Malted Barley, Milled Rice, Oats, Rough Rice, Sorghum, Wheat, Wheat Bran, Wheat Flour and Wheat Midds.
ROSA FAST5 Aflatoxin Quantitative Test Kit – Charm approved commodities for: Barley, Basmati Rice, Brewer’s Rice, Brown Rice, Corn, Corn Flour, Corn Germ Meal, Corn Gluten Meal, Corn Meal, Corn Screenings, Corn/Soy Blend, DDG, DDGS, Flaking Corn Grits, Hominy, Milled Rice, Millet, Oats, Popcorn, Rough Rice, Rye, Sorghum, Soybeans, Wheat and Wheat Flour.
ROSA FAST5 Fumonisin Quantitative Test Kit – Charm approved commodities for: Barley, Corn, Corn Grits, Millet, Oats, Rough Rice, Sorghum, and Wheat.
Source: http://www.prweb.com/releases/2012/3/prweb9347971.htm
“These ROSA FAST5 quantitative mycotoxin tests have been developed to reduce assay time. Charm Sciences continues to develop high quality economical tests that provide early screening for food producers.” says Dr. Mark Tess, Mycotoxin Product Manager.
We look forward to visiting with you at the Pet Food Forum, Charm Sciences booth #92.
For more information on the ROSA FAST5 family of mycotoxin tests, click here http://www.charm.com/en/feed-and-grain/feed-and-grain-mycotoxins.html
About Charm Sciences, Inc.
Charm Sciences is a world leader provider of food safety, water quality and environmental diagnostics. Charm’s diagnostics portfolio includes test kits and systems for mycotoxins, antibiotics, pesticides, alkaline phosphatase, pathogens, end product microbial assessment, allergen control, water quality and ATP hygiene. Directly and through its network of distributors, Charm products serve the food, beverage, water, pharmaceutical, medical, personal care, environmental, and industrial markets in more than 100 countries. Customers rely on Charm products for excellence in quality, innovation and customer support.
© 2012 Charm and ROSA are registered trademarks of Charm Sciences, Inc.
Source: http://www.prweb.com/releases/2012/3/prweb9347971.htm
Posted under BioInformatics, North America, R & D, Reagents, Reports, Research Projects | Comments Off
Cosmic Rays Alter Chemistry of Lunar Ice, May Create Building Blocks of Life
Last Updated on Thursday, 5 April 2012 07:17 Written by Editor Thursday, 5 April 2012 07:17
Space scientists from the University of New Hampshire and multi-institutional colleagues report they have quantified levels of radiation on the moon’s surface from galactic cosmic ray (GCR) bombardment that over time causes chemical changes in water ice and can create complex carbon chains similar to those that help form the foundations of biological structures. In addition, the radiation process causes the lunar soil, or regolith, to darken over time, which is important in understanding the geologic history of the moon.
The scientists present their findings in a paper published online in the American Geophysical Union’s Journal of Geophysical Research (JGR). The paper, titled “Lunar Radiation Environment and Space Weathering from the Cosmic Ray Telescope for the Effects of Radiation (CRaTER),” is based on measurements made by the CRaTER instrument onboard NASA’s Lunar Reconnaissance Orbiter (LRO) mission. The paper’s lead author is Nathan Schwadron, an associate professor of physics at the UNH Space Science Center within the Institute for the Study of Earth, Oceans, and Space (EOS). Co-author Harlan Spence is the director of EOS and lead scientist for the CRaTER instrument.
The telescope provides the fundamental measurements needed to test our understanding of the lunar radiation environment and shows that “space weathering” of the lunar surface by energetic radiation is an important agent for chemical alteration. CRaTER measures material interactions of GCRs and solar energetic particles (SEPs), both of which present formidable hazards for human exploration and spacecraft operations. CRaTER characterizes the global lunar radiation environment and its biological impacts by measuring radiation behind a “human tissue-equivalent” plastic.
Serendipitously, the LRO mission made measurements during a period when GCR fluxes remained at the highest levels ever observed in the space age due to the sun’s abnormally extended quiet cycle. During this quiescent period, the diminished power, pressure, flux and magnetic flux of the solar wind allowed GCRs and SEPs to more readily interact with objects they encountered — particularly bodies such as our moon, which has no atmosphere to shield the blow.
“This has provided us with a unique opportunity because we’ve never made these types of measurements before over an extended period of time, which means we’ve never been able to validate our models,” notes Schwadron. “Now we can put this whole modeling field on more solid footing and project GCR dose rates from the present period back through time when different interplanetary conditions prevailed.” This projection will provide a clearer picture of the effects of GCRs on airless bodies through the history of the solar system.
Moreover, CRaTER’s recent findings also provide further insight into radiation as a double-edge sword. That is, while cosmic radiation does pose risks to astronauts and even spacecraft, it may have been a fundamental agent of change on celestial bodies by irradiating water ice and causing chemical alterations. Specifically, the process releases oxygen atoms from water ice, which are then free to bind with carbon to form large molecules that are “prebiotic” organic molecules.
In addition to being able to accurately gauge the radiation environment of the past, the now more robust models can also be used more effectively to predict potential radiation hazards spawned by GCRs and SEPs.
Says Schwadron, “Our validated models will be able to answer the question of how hazardous the space environment is and could be during these high-energy radiation events, and the ability to do this is absolutely necessary for any manned space exploration beyond low-Earth orbit.”
Indeed, current models were in agreement with radiation dose rates measured by CRaTER, which together demonstrates the accuracy of the Earth-Moon-Mars Radiation Environment Module (EMMREM) being developed at UNH. EMMREM integrates a variety of models describing radiation effects in the Earth-moon-Mars and interplanetary space environments and has now been validated to show its suitability for real-time space weather prediction.
Additional co-authors on the UNH CRaTER team include Thomas Baker, Michael Golightly, Andrew Jordan, Colin Joyce, Sonya Smith, and Jody Wilson. Other co-authors are from the Aerospace Corporation, Harvard-Smithsonian Center for Astrophysics, NASA Goddard Space Flight Center, Boston University, NASA Headquarters, Scientific Data Processing, University of Tennessee, Southwest Research Institute.
Source: http://www.sciencedaily.com/releases/2012/03/120319135245.htm
Posted under North America, Press Releases, Research Projects | Comments Off
Acupuncture and Chinese herbal medicine may help women with chronic pelvic pain
Last Updated on Tuesday, 3 April 2012 05:28 Written by Editor Tuesday, 3 April 2012 05:28
Acupuncture and Chinese herbal medicine may have a role to play in the treatment of health problems linked to chronic pelvic pain (CPP), say experts from the Royal College of Obstetricians and Gynaecologists (RCOG) in a new opinion paper published today.
Professor George Lewith, from the Complementary and Integrated Medicine Research Unit, University of Southampton, was the lead author of the paper entitled, Acupuncture and Chinese herbal medicine for women with chronic pelvic pain.
The paper, constructed by the RCOG’s Scientific Advisory Committee, looks at the evidence relating to the use of some complementary and alternative medicine interventions in the treatment of diseases that are known to be associated with, and cause, CPP.
It is estimated that one in six women are affected by CPP which can be defined as intermittent or constant pain in the lower abdomen or pelvis for over six months and many will use some form of complementary medicine to help their symptoms.
Acupuncture is a safe intervention and involves the insertion of fine needles into specific points on the body. Stimulation of these points is believed to induce a local and systemic healing response.
A literature search, by the paper’s authors, did not find any trials of acupuncture relating specifically to CPP; however, it did identify trials on closely related conditions such as dysmenorrhoea, pelvic inflammatory disease and IBS. These are all known to contribute to CPP.
Two small trials included in a recent Cochrane review found that acupuncture treatment significantly reduced menstrual symptoms compared to standard non-steroidal anti-inflammatory drugs. However more research is needed in this area.
The opinion paper recommends that anyone considering acupuncture treatment should find a practitioner registered with one of the major acupuncture associations such as the British Acupuncture Council, the Association of Traditional Chinese Medicine, and the British Medical Acupuncture Society.
Chinese herbal medicine (CHM) developed alongside acupuncture in China and other East Asian countries over 2000 years ago.
A Cochrane review of CHM for dysmenorrhoea included 39 randomised controlled trials and reported promising results for CHM when compared to the use of pharmaceutical drugs such as NSAIDs and the oral contraceptive pill. However there are limitations as some trials had poor methodological quality and small sample sizes.
The paper recommends that people only consult members of the Register of Chinese Herbal Medicine or the Association of Traditional Chinese Medicine.
In conclusion, the authors of the paper say that while there is no compelling evidence that acupuncture or CHM are effective in the treatment of CPP, they may have roles to play in the treatment of dysmenorrhoea, endometriosis, IBS and pelvic inflammatory disease.
Moreover, women should be aware of the provisional nature of the evidence supporting these alternative approaches.
Professor George Lewith says: “Some small trials suggest that acupuncture and Chinese herbal medicine may be beneficial for chronic pelvic pain. However, the current evidence lacks rigour and the available trials are poorly designed and inadequately reported so we can only consider this preliminary evidence.
“Many women use acupuncture and Chinese herbal medicine for chronic pelvic pain so this area clearly requires further rigorous investigation and we would support further well-designed research for this problematic condition.
Source: http://medicalxpress.com/news/2012-03-acupuncture-chinese-herbal-medicine-women.html
Posted under Europe, Natural Products, Reports, Research Projects | Comments Off
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory